If you cannot access ON24, please view here.
The role of SBRT in local ablation of oligometastatic or locally progressive gynecologic cancers will be reviewed. Ongoing studies and future directions in utilization of SBRT in this patient group will also be discussed. SBRT as a primary boost for gynecologic cancers will be evaluated, in scenarios where brachytherapy is not desired or possible. Patient cases will be examined including possible challenges and strategies to address them. SBRT as re-treatment for recurrences in the pelvis or para-aortic region, including experience with radiotherapy doses utilized and toxicity will be discussed.
Learning objectives:
1. Review current evidence in the role of Stereotactic body radiotherapy (SBRT) for oligometastatic gynecologic cancers
2. Discuss clinical cases where SBRT may be considered as a primary boost for gynecologic cancers, where brachytherapy is not desirable or feasible
3. Understand current literature regarding SBRT for re-irradiation in the pelvis for recurrences of gynecologic cancers
Presenter: Elysia Donovan, M.D.
Radiation Oncologist, Juravinski Cancer Centre and Assistant Professor, McMaster University, Ontario, Canada
Elysia Donovan is a radiation oncologist at the Juravinski Cancer Centre and Assistant Professor at McMaster University, Ontario, Canada. She has a clinical focus in gynecologic cancers and breast cancers, and completed a clinical research fellowship in multi-site stereotactic body radiotherapy (SBRT). She previously completed a masters in Health Research Methodology, Clinical Epidemiology, at McMaster University. Her research interests include stereotactic body radiotherapy for oligometastasis in gynecologic and breast cancers, image-guided brachytherapy for cervical and recurrent gynecologic cancers, and clinical trials.
Moderator: Susan Lalondrelle, M.D., FRCR, MRCP, BM, BSc
Consultant Clinical Oncologist, Lead for Clinical Oncology, The Royal Marsden NHS Foundation Trust, London, UK and Honorary Faculty ICR, London, UK
Dr Lalondrelle is a Consultant Clinical Oncologist at the Royal Marsden Hospital, specialising in the treatment of gynaecological cancers with radiotherapy, brachytherapy and chemotherapy. She also holds Honorary Faculty status at the Institute of Cancer Research. She qualified from the University of Southampton in 1998 and trained in oncology at The Royal Marsden and in South West Thames, completing her research thesis in adaptive radiotherapy for pelvic cancers at the University of London.
Dr Lalondrelle is actively involved in clinical research with particular interests in radiotherapy technologies, particularly stereotactic radiotherapy and adaptive planning to improve accuracy and reduce toxicity. She is the global lead for the gynaecology group of the MRlinac consortium. She is also involved in image-guided brachytherapy, the assessment of functional imaging for radiotherapy planning and the combination of biological and immunotherapy agents with radiotherapy.
